These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22115012)

  • 1. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case-control study.
    Bühler KF; Fischer R
    Gynecol Endocrinol; 2012 May; 28(5):345-50. PubMed ID: 22115012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
    Chen MJ; Yi YC; Guu HF; Chen YF; Kung HF; Chang JC; Chuan ST; Chen LY
    Front Endocrinol (Lausanne); 2022; 13():931756. PubMed ID: 36046790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
    Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
    Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
    Chang JC; Yi YC; Chen YF; Guu HF; Kung HF; Chen LY; Chuan ST; Chang YM; Chen MJ
    Arch Gynecol Obstet; 2024 Feb; 309(2):699-706. PubMed ID: 38099955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study.
    Tarlatzis B; Tavmergen E; Szamatowicz M; Barash A; Amit A; Levitas E; Shoham Z
    Hum Reprod; 2006 Jan; 21(1):90-4. PubMed ID: 16172149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.
    De Placido G; Alviggi C; Perino A; Strina I; Lisi F; Fasolino A; De Palo R; Ranieri A; Colacurci N; Mollo A;
    Hum Reprod; 2005 Feb; 20(2):390-6. PubMed ID: 15576390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol: a meta-analysis.
    Oliveira JB; Mauri AL; Petersen CG; Martins AM; Cornicelli J; Cavanha M; Pontes A; Baruffi RL; Franco JG
    J Assist Reprod Genet; 2007; 24(2-3):67-75. PubMed ID: 17195098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.
    Lehert P; Kolibianakis EM; Venetis CA; Schertz J; Saunders H; Arriagada P; Copt S; Tarlatzis B
    Reprod Biol Endocrinol; 2014 Feb; 12():17. PubMed ID: 24555766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study.
    Franco JG; Baruffi RL; Oliveira JB; Mauri AL; Petersen CG; Contart P; Felipe V
    Reprod Biol Endocrinol; 2009 Jun; 7():58. PubMed ID: 19497101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study.
    Humaidan P; Bungum M; Bungum L; Yding Andersen C
    Reprod Biomed Online; 2004 Jun; 8(6):635-43. PubMed ID: 15169576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study.
    Matorras R; Prieto B; Exposito A; Mendoza R; Crisol L; Herranz P; Burgués S
    Reprod Biomed Online; 2009 Dec; 19(6):879-87. PubMed ID: 20031032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study.
    Papanikolaou EG; Verpoest W; Fatemi H; Tarlatzis B; Devroey P; Tournaye H
    Fertil Steril; 2011 Mar; 95(3):1174-7. PubMed ID: 20979997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response.
    De Placido G; Mollo A; Clarizia R; Strina I; Conforti S; Alviggi C
    Fertil Steril; 2006 Jan; 85(1):247-50. PubMed ID: 16412769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Lh polymorphisms and r-hLh supplementation in GnRh agonist treated ART cycles: A cross sectional study.
    G A R; Cheemakurthi R; Prathigudupu K; Balabomma KL; Kalagara M; Thota S; Kota M
    Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():119-125. PubMed ID: 29408742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART.
    Firouzabadi RD; Ahmadi S; Oskouian H; Davar R
    Arch Gynecol Obstet; 2010 Jan; 281(1):81-5. PubMed ID: 19357861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years.
    Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
    Reprod Biomed Online; 2024 Jun; 48(6):103725. PubMed ID: 38593745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures.
    Ruvolo G; Bosco L; Pane A; Morici G; Cittadini E; Roccheri MC
    Fertil Steril; 2007 Mar; 87(3):542-6. PubMed ID: 17126339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evaluation of recombinant LH supplementation in patients with suboptimal response to recombinant FSH undergoing IVF treatment with GnRH agonist down-regulation.
    Yazıcı Yılmaz F; Görkemli H; Çolakoğlu MC; Aktan M; Gezginç K
    Gynecol Endocrinol; 2015 Feb; 31(2):141-4. PubMed ID: 25237892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.